Compare SRRK & LAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | LAD |
|---|---|---|
| Founded | 2012 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.3B |
| IPO Year | 2018 | 1996 |
| Metric | SRRK | LAD |
|---|---|---|
| Price | $41.57 | $297.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | $70.44 | ★ $409.07 |
| AVG Volume (30 Days) | ★ 1.8M | 286.7K |
| Earning Date | 11-13-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 0.96% |
| EPS Growth | N/A | ★ 9.01 |
| EPS | N/A | ★ 15.68 |
| Revenue | N/A | ★ $11,821,400,000.00 |
| Revenue This Year | N/A | $1.84 |
| Revenue Next Year | $2,404.46 | $3.26 |
| P/E Ratio | ★ N/A | $18.81 |
| Revenue Growth | N/A | ★ 17.20 |
| 52 Week Low | $27.07 | $239.78 |
| 52 Week High | $61.76 | $439.49 |
| Indicator | SRRK | LAD |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 40.11 |
| Support Level | $39.69 | $283.88 |
| Resistance Level | $48.59 | $307.40 |
| Average True Range (ATR) | 1.89 | 10.48 |
| MACD | -0.23 | 2.20 |
| Stochastic Oscillator | 14.72 | 48.94 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Lithia Motors is a retailer of new and used vehicles and related services. The company offers nearly 60 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US. We expect more deals over time in the US and, at times, abroad. Annual revenue in 2025 was $37.6 billion, and we see over $50 billion possible in a few years. The US was 78.5% of 2025 revenue and the UK second at 18.4%, due to the 2024 Pendragon acquisition. In 2025, new vehicle sales were about 50% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.